ClinicalTrials.Veeva

Menu
S

Sierra Eye Associates | Reno, NV

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
KSI-301
Aflibercept
Lampalizumab
UBX1325
APL-2
Faricimab
THR-149
GB-102
Sunitinib Malate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 89 total trials

4D-150 in Patients With Diabetic Macular Edema

Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).

Enrolling
Diabetic Macular Edema
Diabetic Retinopathy
Biological: Aflibercept IVT
Biological: 4D-150 IVT

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: 4D-150 IVT
Biological: Aflibercept IVT

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting
Diabetic Retinopathy
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Enrolling
Neovascular Age-related Macular Degeneration
Device: SUSVIMO PDS Implant
Drug: LUCENTIS (ranibizumab injection)
Locations recently updated

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is...

Enrolling
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Biological: EXG102-031

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange
Locations recently updated

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Active, not recruiting
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Other: Sham Procedure

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Active, not recruiting
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who wer...

Invitation-only
Wet Macular Degeneration
Neovascular Age-related Macular Degeneration
Genetic: RGX-314

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been tr...

Invitation-only
Age Related Macular Degeneration (AMD)
Genetic: GT005

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

Trial sponsors

Roche logo
Genentech logo
AbbVie logo
Kodiak Sciences logo
G
T
A
U
4
Allergan logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems